Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Net Income Loss of -$10.31 million for the year ending 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +11.3% in Net Income Loss from 2024 to 2025.
- This data is from BRAINSTORM CELL THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2004 to 2025 (22 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$2.11 million | Q2 2014: -$1.98 million | Q3 2014: -$2.42 million | Q1 2015: -$2.24 million | Q2 2015: -$2.27 million | Q3 2015: -$2.60 million | Q1 2016: -$1.79 million | Q2 2016: -$962.0 thousand | Q3 2016: -$1.61 million | Q1 2017: -$1.79 million | Q2 2017: -$1.04 million | Q3 2017: -$2.40 million | Q1 2018: -$2.30 million | Q2 2018: -$3.09 million | Q3 2018: -$3.18 million | Q1 2019: -$5.03 million | Q2 2019: -$4.90 million | Q3 2019: -$5.63 million | Q1 2020: -$8.11 million | Q2 2020: -$7.39 million | Q3 2020: -$4.49 million | Q1 2021: -$6.66 million | Q2 2021: -$6.27 million | Q3 2021: -$5.34 million | Q1 2022: -$5.36 million | Q2 2022: -$7.04 million | Q3 2022: -$6.86 million | Q1 2023: -$5.06 million | Q2 2023: -$5.33 million | Q3 2023: -$1.23 million | Q1 2024: -$3.40 million | Q2 2024: -$2.54 million | Q3 2024: -$2.71 million | Q1 2025: -$2.86 million | Q2 2025: -$2.90 million | Q3 2025: -$2.11 million.
- Over the full 22 years of available data (2004 to 2025), BRAINSTORM CELL THERAPEUTICS INC.'s Net Income Loss has declined by 14,019.2%.
- Historical annual values: Fiscal year 2025: -$10.31 million | Fiscal year 2024: -$11.62 million | Fiscal year 2023: -$17.19 million | Fiscal year 2022: -$24.28 million | Fiscal year 2021: -$24.46 million | Fiscal year 2020: -$31.81 million | Fiscal year 2019: -$23.25 million | Fiscal year 2018: -$13.95 million | Fiscal year 2017: -$4.95 million | Fiscal year 2016: -$4.98 million | Fiscal year 2015: -$8.49 million | Fiscal year 2014: -$9.25 million | Fiscal year 2013: -$4.90 million | Fiscal year 2012: -$3.43 million | Fiscal year 2011: -$3.92 million | Fiscal year 2010: -$2.42 million | Fiscal year 2009: -$1.78 million | Fiscal year 2008: -$3.47 million | Fiscal year 2007: -$6.24 million | Fiscal year 2006: -$3.32 million | Fiscal year 2005: -$18.84 million | Fiscal year 2004: -$73.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: